TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of patients with adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of delayed Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Characterization of lung cells associated with pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cut-off value of SUVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of quantitative EUS-E (strain ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Adverse event morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse event morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-Normalized AUC0-24 of R-Methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized AUC0-24 of S-Methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Who Increased Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of single lateral steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BrAC Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Recurrent Suicidal Events
Endpoint domain: Adverse events/effects
Primary endpoint: Kaposi sarcoma progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: intraoperative reduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of SL-172154
Endpoint domain: Adverse events/effects
Primary endpoint: Peak plasma concentration of JNJ-40411813
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the peak plasma concentration of JNJ-40411813
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration of JNJ-40411813-time curve from 0 to t hours post dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Evaluated for Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in High Density Lipoprotein Cholesterol (HDLc) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of major structural malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pattern of major malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: VAS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral accessibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physician's Wound Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient's Global Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Histological Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of NASH and no Worsening of Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: acute and late GI/GU toxicity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of improved subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital Clavien-Dindo > 3 complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Labor market attachment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Progression to threshold ROP requiring surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: identity development
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: peer relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: family relationships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: First Day Free From Symptoms of Phototoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV transmission risk events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean change in dark adaptation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Response Off Treatment (SRoT) by 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural activity during social reward processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: functional connectivity during social reward processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole-body Protein Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-body Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-body Protein Breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal Fluency Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fronto behavioral Index (FBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALS Functional Rating Scale Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete renal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Symptoms Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Percent of Volume Opacified (APOV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semiquantitative assessment of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Nitric Oxide Dependent Vasodilation in the Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-reported pain persistence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Volume change of primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Magnetic resonance imaging spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory blockade evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average rate of chronic hepatitis B accepting antiviral treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: DNA genomic sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression profile using microarray assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mutation mapping using the OncoMap and other genotyping techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of sustained islet allograft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of de novo germline mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease of hemolysis after eculizumab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The required Unit of pRBC transfusion before and after eculizumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dry eye severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuations due to gastrointestinal adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of patients with complete exclusion of the LAA measured with TEE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Average AM Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in performance on the QB Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electrophysiological (EEG) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients in Treatment Free Remission (TFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of new mutations from ctDNA analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the frequency of mutations from WES analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance between WES analyses of serial tumor biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Western Ontario McMasters Osteoarthritis Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with live birth
Endpoint domain: Mortality/survival
Primary endpoint: Total Symptom Score (TSS) (excluding tiredness)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual acuity including distance and near vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric mucosal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Long term safety evaluations
Endpoint domain: Adverse events/effects
Primary endpoint: 7-day point prevalence abstinence at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-day point prevalence abstinence at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of 3H-palmitate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neutralizing Antibodies Titer to SPK-3006 capsid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean urine carbamazepine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Contralesional Corticospinal Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline Finger Tracking Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Achieving PASI 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of No Exudate Leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in postural sway/balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rapid measure of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in measure of inducible dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO Output (Ppm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABG (COHb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal probing depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-reported Degree of Pain in the Neck-shoulder Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the number of renal replacement therapy (RRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean difference score of professional competence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic accuracy of coronary scanner
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sedation Failures and Use of Rescue Medications
Endpoint domain: Adverse events/effects
Primary endpoint: Time of Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage Change in Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients with psychosocial problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: modified stock ankylosing spondylitis spine (mSASS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bath ankylosing spondylitis radiographic index (BASRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Innocuous static tactile sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief (no or mild pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of photophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of phonophobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Accelerometers_Vector Magnitude Average Counts(VMA) at Post Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bypass permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Number of Steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinical/biological events related to HIV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Patients With no Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Depression, Anxiety, and Stress Scales-21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speech articulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phonemic awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of allosensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Collection of blood, ascites, and pleural effusion samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment and restoration of normal hematopoiesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: longitudinal development of cGVHD in the oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale for Suicide Ideation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Psychiatric Rating Scale for Anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of AS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal toxicity associated with genetic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Email Opened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Link Clicked
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose based on incidence of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypic characterizations of stroke patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distinguishing benign from malignant tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients requiring NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of NIV failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIV related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Accurate Understanding of Chemotherapy Benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of RTX in reducing severe refractory pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of MRI fluoroscopy catheter navigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of MRI fluoroscopy catheter navigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Glycemic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Parents Hypoglycemia Fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Treatment morbidity induced versus quality of life based on duration of hormonal therapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End-tidal Oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End-tidal Carbon Dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Outcomes of ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cause of Early TKA Revision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline FFR at 6 months after CTO PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Myocardial perfusion at 6 months after CTO PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Myocardial Viability at 6 months after CTO PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hematologic response (HI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Smoking Cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Complete Response or Very Good Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Response, Very Good Partial Response, or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from local progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Evaluable Patients Who Died
Endpoint domain: Mortality/survival
Primary endpoint: Glutamate concentration in ventral striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vitamin E Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete remission percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes